EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: A case report and review of the literature

Yiming Fan, Rui Yin

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112762 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yiming Fan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Janus Kinase Inhibitors, Piperidines, Psoriasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Palmoplantar pustulosis (PPP) is a chronic inflammatory recurrent disease characterized by sterile pustules involving palms and/or feet. Presently, there are no standard recommended treatment regimens. Tofacitinib is an oral Janus kinase (JAK) inhibitor, mainly acts on JAK 1 and 3 and has been approved for the treatment of rheumatoid arthritis in adults. Herein, we present a case of a patient with PPP who did not respond to IL-17A inhibitor secukinumab but was successfully treated by the JAK inhibitor tofacitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedJanus Kinase InhibitorsPiperidinesPsoriasisPyrimidinesHumansDrug SubstitutionInterleukin-17PyrrolesTreatment Outcome

Stichwörter der Autor:innen

IL-17A inhibitorJAK inhibitorPalmoplantar pustulosisSecukinumabTofacitinib

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-17Janus Kinase InhibitorsPiperidinesPyrimidinesPyrrolessecukinumabtofacitinib

Autor:innen und Institutionen

  • Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
  • Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China. Electronic address: swyinrui@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Fan, Y., & Yin, R. (2024). Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: A case report and review of the literature. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112762

Vancouver

Fan Y, Yin R. Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: A case report and review of the literature. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112762

BibTeX
@article{Fan2024,
  author = {Fan, Yiming and Yin, Rui},
  title = {Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: A case report and review of the literature},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112762}
}
Kostenlos starten →